New pill shows promise against tough breast cancer
NCT ID NCT04505826
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new oral drug called OP-1250 in 153 adults with advanced or metastatic hormone-receptor-positive, HER2-negative breast cancer. The drug works by blocking estrogen receptors more completely than current therapies. The trial aimed to find the best dose, check safety, and see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OP-1250 (a new oral drug that blocks estrogen receptors)
What this could lead to
If successful, this could provide a new treatment option for people with advanced hormone-receptor-positive breast cancer that has stopped responding to current hormone therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 153 participants, so results may not apply to all patients. The drug may cause side effects or fail to shrink tumors in many cases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health
Orlando, Florida, 32804, United States
-
Cancer Research South Australia
Adelaide, South Australia, 5000, Australia
-
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Center
Sarasota, Florida, 34232, United States
-
ICON Cancer Centre
Auchenflower, Queensland, 4066, Australia
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Macquarie University
Sydney, New South Wales, 2109, Australia
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
UCLA Hematology/Oncology
Los Angeles, California, 90404, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Miami, Sylvester Comprehensive Cancer Center
Deerfield Beach, Florida, 33442, United States
-
Westmead
Westmead, New South Wales, 2145, Australia
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States